ダイチョウガン ノ サイシン ノ シンダン チリョウ
Progress of diagnosis and treatment for colorectal cancer
Miyamoto, Hiroshi Department of Gastroenterology and Oncology, Institute of Biomedical Sciences, Tokushima University Graduate School Tokushima University Educator and Researcher Directory KAKEN Search Researchers
endoscopic submucosal dissection
molecular target drug
Colorectal cancer has the third mortality in 2013 and the second morbidity in 2011 of all cancers in Japan. Therefore, it is very important to know the newest information about colorectal cancer. The latest endoscopy has been equipped with not also magnifying function but image enhancing function, such as narrow band imaging and blue laser imaging. These functions enable us to know distinguish benign from malignancy of colorectal polyps without a biopsy. As a therapeutic progress, endoscopic submucosal dissection for the early colorectal cancer has been spread due to approval by the Japanese health insurance system in 2012. Drug therapy for the colorectal cancer has progressed due to the new drug and regimen. Above all, the molecular target drug has improved the prognosis of stage IV colorectal cancer with or without other chemotherapy.The molecular target drugs for colorectal cancer are currently anti VEGF antibody（bevacizumab）and anti EGFR antibody（cetuximab, panitumumab）in clinical use. Moreover, regorafenib and TAS-102 showed efficacy for the colorectal cancer and have been in clinical use. As a result, overall survival rate of stage IV colorectal cancer has reached more than３０months in case of use up all these drugs.
sam_72_1-2_5.pdf 668 KB